AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Stock Based Compensation

Last Annual Value

22.09M

3-Year CAGR

56%

5-Year CAGR

44%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Stock Based Compensation

SPRY · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
22.09M
33.7%50.8%N/A 
6.95M
-9.2%1.6%-15.9%
SVRA logo
Savara Inc.
NASDAQ:SVRA
14.42M
51.1%34.6%52.7%
37.11M
9.7%9.5%33.3%
6.40M
119.8%N/AN/A
12.55M
110.6%N/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
25.34M
-6.3%105.0%N/A
28.01M
N/A57.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
7.12M
-0.7%12.4%6.6%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07